HK1058193A1 - Treatment of gastrointestinal stromal tumors - Google Patents

Treatment of gastrointestinal stromal tumors

Info

Publication number
HK1058193A1
HK1058193A1 HK03109439A HK03109439A HK1058193A1 HK 1058193 A1 HK1058193 A1 HK 1058193A1 HK 03109439 A HK03109439 A HK 03109439A HK 03109439 A HK03109439 A HK 03109439A HK 1058193 A1 HK1058193 A1 HK 1058193A1
Authority
HK
Hong Kong
Prior art keywords
treatment
gastrointestinal stromal
stromal tumors
methylpiperazin
ylamino
Prior art date
Application number
HK03109439A
Other languages
English (en)
Inventor
Elisabeth Buchdunger
Renaud Capdeville
George Daniel Demetri
Sasa Dimitrijevic
Brian J Druker
Jonathan A Fletcher
Heikki Joensuu
Sandra Leta Silberman
David Tuveson
Michael C Heinrich
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22920224&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1058193(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1058193A1 publication Critical patent/HK1058193A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK03109439A 2000-10-27 2003-12-29 Treatment of gastrointestinal stromal tumors HK1058193A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24381000P 2000-10-27 2000-10-27
PCT/EP2001/012442 WO2002034727A2 (en) 2000-10-27 2001-10-26 Treatment of gastrointestinal stromal tumors

Publications (1)

Publication Number Publication Date
HK1058193A1 true HK1058193A1 (en) 2004-05-07

Family

ID=22920224

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03109439A HK1058193A1 (en) 2000-10-27 2003-12-29 Treatment of gastrointestinal stromal tumors

Country Status (26)

Country Link
US (1) US6958335B2 (ru)
EP (1) EP1332137B1 (ru)
JP (1) JP4386635B2 (ru)
KR (1) KR100885129B1 (ru)
CN (1) CN1276754C (ru)
AT (1) ATE321556T1 (ru)
AU (2) AU1826202A (ru)
BR (1) BRPI0114870B8 (ru)
CA (1) CA2424470C (ru)
CY (1) CY1105055T1 (ru)
CZ (1) CZ303944B6 (ru)
DE (1) DE60118430T2 (ru)
DK (1) DK1332137T3 (ru)
ES (1) ES2260317T3 (ru)
HK (1) HK1058193A1 (ru)
HU (1) HU229106B1 (ru)
IL (2) IL155029A0 (ru)
MX (1) MXPA03003703A (ru)
NO (1) NO324948B1 (ru)
NZ (1) NZ525254A (ru)
PL (1) PL209733B1 (ru)
PT (1) PT1332137E (ru)
RU (1) RU2301066C2 (ru)
SK (1) SK287335B6 (ru)
WO (1) WO2002034727A2 (ru)
ZA (1) ZA200302155B (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2253319A1 (en) * 2001-05-16 2010-11-24 Novartis AG Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent.
WO2003004006A2 (en) * 2001-06-29 2003-01-16 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
ATE330608T1 (de) * 2001-06-29 2006-07-15 Ab Science Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen
JP2005500041A (ja) * 2001-06-29 2005-01-06 アブ サイエンス 強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤
ATE343415T1 (de) * 2001-06-29 2006-11-15 Ab Science Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen
PT1401413E (pt) * 2001-06-29 2007-02-28 Ab Science Uso de inibidores da tirosina cinase para tratar doenças alérgicas
JP2005511506A (ja) * 2001-09-20 2005-04-28 アブ サイエンス 間質性膀胱炎を治療するための強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤の使用方法
CA2461182A1 (en) * 2001-09-20 2003-05-01 Ab Science Use of tyrosine kinase inhibitors for promoting hair growth
AU2003216625A1 (en) * 2002-02-27 2003-09-09 Ab Science Use of tyrosine kinase inhibitors for treating cns disorders
FR2844452A1 (fr) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Utilisation d'inhibiteurs specifiques de tyrosine kinases pour l'immunomodulation
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US20080096864A1 (en) * 2003-09-19 2008-04-24 Sasa Dimitrijevic Treatment Of Gastrointestinal Stromal Tumors With Imatinib And Midostaurin
US20100210596A1 (en) * 2006-02-01 2010-08-19 Bluestone Jeffrey A Use of aminopyrimidine compounds in the treatment of immune disorders
KR101433629B1 (ko) * 2006-09-11 2014-08-27 쿠리스 인코퍼레이션 아연 결합 부분을 함유한 티로신 키나아제 억제제
EP2061772A4 (en) * 2006-09-11 2011-06-29 Curis Inc MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US20090082361A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched imatinib
CN101584696A (zh) 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
WO2010120386A1 (en) 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
WO2012122058A2 (en) 2011-03-04 2012-09-13 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
WO2012155339A1 (zh) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
EP2817030A1 (en) 2012-02-21 2014-12-31 Ranbaxy Laboratories Limited Stable dosage forms of imatinib mesylate
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
MX2015001194A (es) 2012-07-27 2015-11-23 Izumi Technology Llc Composiciones inhibidoras de eflujo y metodos de tratamiento que usan las mismas.
AU2014296032A1 (en) 2013-07-31 2016-03-17 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
US11285152B2 (en) 2017-07-20 2022-03-29 Kashiv Biosciences, Llc Stable oral pharmaceutical composition of imatinib
CN111818915B (zh) 2018-01-31 2024-05-24 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
KR20220045189A (ko) 2019-08-12 2022-04-12 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양을 치료하는 방법
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
EP4327827A3 (en) 2019-12-30 2024-05-29 Deciphera Pharmaceuticals, LLC Amorphous kinase inhibitor formulations and methods of use thereof
JP2023509628A (ja) 2019-12-30 2023-03-09 デシフェラ・ファーマシューティカルズ，エルエルシー １－（４－ブロモ－５－（１－エチル－７－（メチルアミノ）－２－オキソ－１，２－ジヒドロ－１，６－ナフチリジン－３－イル）－２－フルオロフェニル）－３－フェニル尿素の組成物
KR102535840B1 (ko) 2020-07-31 2023-05-23 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 위장관기질종양 예방, 개선 또는 치료 용도
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (ru) * 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
EP1117397A1 (en) * 1998-08-31 2001-07-25 Sugen, Inc. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity

Also Published As

Publication number Publication date
ES2260317T3 (es) 2006-11-01
US20040023976A1 (en) 2004-02-05
RU2301066C2 (ru) 2007-06-20
MXPA03003703A (es) 2005-01-25
DE60118430D1 (de) 2006-05-18
CA2424470A1 (en) 2002-05-02
CZ20031152A3 (en) 2004-04-14
IL155029A0 (en) 2003-10-31
CN1622808A (zh) 2005-06-01
NO324948B1 (no) 2008-01-07
CZ303944B6 (cs) 2013-07-10
ZA200302155B (en) 2004-04-22
SK5182003A3 (en) 2004-02-03
PT1332137E (pt) 2006-07-31
US6958335B2 (en) 2005-10-25
DE60118430T2 (de) 2006-10-26
PL362148A1 (en) 2004-10-18
CA2424470C (en) 2009-06-09
CN1276754C (zh) 2006-09-27
DK1332137T3 (da) 2006-07-17
BR0114870A (pt) 2004-02-17
EP1332137B1 (en) 2006-03-29
BRPI0114870B8 (pt) 2021-05-25
HU229106B1 (en) 2013-07-29
HUP0301512A2 (hu) 2003-11-28
IL155029A (en) 2009-09-22
SK287335B6 (sk) 2010-07-07
NZ525254A (en) 2006-02-24
EP1332137A2 (en) 2003-08-06
BRPI0114870B1 (pt) 2020-06-16
CY1105055T1 (el) 2010-03-03
KR100885129B1 (ko) 2009-02-23
AU1826202A (en) 2002-05-06
WO2002034727A2 (en) 2002-05-02
JP2004512328A (ja) 2004-04-22
ATE321556T1 (de) 2006-04-15
JP4386635B2 (ja) 2009-12-16
AU2002218262B2 (en) 2005-09-29
PL209733B1 (pl) 2011-10-31
NO20031833D0 (no) 2003-04-24
WO2002034727A3 (en) 2003-03-27
KR20030051656A (ko) 2003-06-25
NO20031833L (no) 2003-04-24

Similar Documents

Publication Publication Date Title
HK1058193A1 (en) Treatment of gastrointestinal stromal tumors
HK1028599A1 (en) Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
TWI347186B (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
HK1072192A1 (en) Treatment of rheumatoid arthritis using imatinib
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
IL171927A0 (en) Use of tyrosine kinase inhibitor to treat diabetes
AU2003216621A8 (en) Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
WO2004103374A3 (en) Imatinib combinations for head and neck cancers
AU2003209521A1 (en) Use of 4-(4-methylpiperazin-1-ylmethyl)-n(4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl)-benzamide for treating seminomas
NZ610401A (en) Inhibitors of the mutant form of kit

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20211025